Quest Partners LLC Purchases 1,572 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Quest Partners LLC raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 391.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,974 shares of the biopharmaceutical company's stock after acquiring an additional 1,572 shares during the quarter. Quest Partners LLC's holdings in Regeneron Pharmaceuticals were worth $2,075,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in REGN. Sachetta LLC increased its position in Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 10 shares during the last quarter. Rakuten Securities Inc. raised its position in Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 19 shares in the last quarter. Stephens Consulting LLC acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $26,000. Crewe Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the first quarter worth approximately $28,000. Finally, Lynx Investment Advisory acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth $33,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Down 2.3 %

NASDAQ REGN traded down $17.40 on Tuesday, reaching $744.60. The company had a trading volume of 979,027 shares, compared to its average volume of 534,680. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52 week low of $736.19 and a 52 week high of $1,211.20. The stock has a market cap of $81.82 billion, a price-to-earnings ratio of 18.44, a PEG ratio of 2.86 and a beta of 0.15. The stock's 50 day moving average is $977.55 and its 200-day moving average is $1,033.65.

Insider Activity at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the business's stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 27.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 7.48% of the company's stock.

Analyst Ratings Changes

Several equities analysts have commented on REGN shares. TD Cowen increased their target price on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a "buy" rating in a research report on Tuesday, July 23rd. Wells Fargo & Company reduced their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an "overweight" rating for the company in a research note on Tuesday, October 22nd. Evercore ISI cut their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating for the company in a research report on Thursday, October 24th. Barclays lowered their target price on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating on the stock in a report on Friday, November 1st. Finally, Royal Bank of Canada lowered their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an "outperform" rating on the stock in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $1,099.55.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.